Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHuPH20 for Nickel Allergic Contact Dermatitis
NCT00928447Phase 2Completed
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Jun 2009
- Primary completion
- Sep 2009
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic contact dermatitis (ACD) comparing rHuPH20 Sites with Placebo Sites (2 arms). Primary endpoints: Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1 at Day 14 and Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 2 at Day 14. Started Jun 2009; status: completed.
02
Drugs
ENHANZE
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT00928447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00928447.